501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies to Beta Test Marijuana Breathalyzer with
Private
Clinic
in Northwestern
U.S.
Cannabix is developing the Cannabix Marijuana Breathalyzer devices
to give law enforcement and employers a tool to enhance public
safety
Vancouver, British
Columbia, April
7, 2021
--
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the workplace, is pleased to report that
it will begin beta testing its
THC
Breath Analyzer ("THCBA")
with a
private drug testing clinic located in
the
Northwestern
United States. Cannabix
expects
to
deliver
its version 3.0
THCBA
prototype
to this
clinic in the coming
weeks to
begin a breath testing with
select patients.
The Company and the clinic have entered into a non-disclosure
agreement. The collaborating
clinic has a robust drug testing operation and is one of the top
drug testing providers to
employers within its respective
state. The high-volume clinic has a diverse range of patients and
focuses on private sector testing for alcohol and illicit
drugs. The
clinic
has extensive experience beta testing with new drug testing
technologies. In the recent past, the collaborating clinic was
selected to be an early tester
of oral swab
devices, which have been
authorized for use in certain jurisdictions.
Beta-testing of
the THCBA
prototype
will
be focused on training
the device's machine learning database, to help
determine
sensitivity ranges
and improving user and administrator experience. Furthermore, this
data will help with identifying cross-reactivity
of
other
substances with the study population. The
THCBA
is a drug
screening device for employers
and other markets who are seeking a way to quickly, easily and
non-invasively test for recent use of ?9-tetrahydrocannabinol
("THC")
- the psychoactive component of marijuana that causes
impairment.
Current forms of testing for
marijuana use can identify THC ranging from minutes to days prior
to actual use, making it difficult to show the difference between
the two. Studies¹
have shown that breath is a better indicator of impairment than
saliva and
urine
because THC is present in breath for a relatively short period of
time (1-3 hours); whereas, it is excreted at detectable levels in
other body fluids for many hours, days, or even weeks after
smoking. This short time period of detection in breath aligns with
the peak impairment window.
(1) Olla P,
Ishraque
MT,
Bartol
S. 2020.
Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration
Trends Postcannabis
Exposure
in Medical Cannabis Patients. Cannabis and Cannabinoid Res.;
99-104.
Himes S.
et al. 2013. Cannabinoids in Exhaled Breath following Controlled
Administration of Smoked Cannabis. Clinical Chemistry;
1780–1789.
Beck
O, Sandqvist
S,
Dubbelboer
I, Franck
J. 2011. Detection of delta9-tetrahydrocannabinol in exhaled breath
collected from cannabis users. J Anal Toxicol;
35:541– 4.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a developer of
marijuana
breathalyzer technologies
for law
enforcement and the workplace. Cannabix is working to develop
drug-screening
devices
that will detect THC- the psychoactive component of marijuana that
causes impairment
using
breath samples. Breath testing for
THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.